Susan Zelt
NGM Biopharmaceuticals (United States)(US)
Publications by Year
Research Areas
HIV/AIDS Research and Interventions, Health Systems, Economic Evaluations, Quality of Life, HIV/AIDS drug development and treatment, HIV Research and Treatment, Breast Cancer Treatment Studies
Most-Cited Works
- → Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)(2014)107 cited
- → Glycine betaine and proline are the principal compatible solutes ofStaphylococcus aureus(1991)49 cited
- → The National Public Health Leadership Institute: Evaluation of a Team-Based Approach to Developing Collaborative Public Health Leaders(2005)48 cited
- → Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development(2016)27 cited
- → Costs associated with complications are lower with capecitabine than with 5‐fluorouracil in patients with colorectal cancer(2009)27 cited
- → A Cost-Effectiveness Analysis between Amlodipine and Angiotensin II Receptor Blockers in Stroke and Myocardial Infarction Prevention among Hypertension Patients in China(2013)18 cited
- Assessing United States Patient and Dermatologist Experiences with Severe Chronic Hand Eczema.(2015)
- → Benefit-risk tradeoff preferences for chronic hand eczema treatments(2016)8 cited
- → Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States(2009)7 cited
- → Capecitabine is associated with lower chemotherapy-related expenditures than those associated with gemcitabine in women with metastatic breast cancer.(2009)5 cited